UBS lowered the firm’s price target on Insulet to $215 from $270 and keeps a Neutral rating on the shares. Current multiples seem to be pricing in an overly bearish view, in which TAMs are cut meaningfully as GLP-1 adoption ramps, specifically in diabetes and obstructive sleep apnea, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- William Blair biotech analyst to hold an analyst/industry conference call
- Early notable gainers among liquid option names on August 30th
- Insider Trading: Insulet (NASDAQ:PODD) Gains as Top Executive Makes Share Purchase
- Insulet CEO buys $1.0M in common stock
- Jefferies healthcare analyst holds an analyst/industry conference call